/

INVA

Innoviva, Inc.Pre-market

21.45+0.24 +1.13%USD

NasdaqGS · as of Oct 12, 16:00 ET · 15m delay

Open

21.27

Prev close

21.21

Day range

21.1221.47

52-week range

16.5225.15

Volume

521.19K0.66×

Mkt cap

1.55B

P/E ttm

5.01

Fwd P/E

9.71

EPS ttm

4.28

Div yield

0.00%

Earnings

—

From 52w high

−14.71%

Price Chart

Yahoo Finance · delayed

INVAOct 12, 2026O 21.27H 21.48L 21.12C 21.45+0.24 (+1.13%)Vol 521.20K

SMA 5020.96
SMA 20021.80

1Y change +23.63% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

INVA Innoviva, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +3.92%
1 month: +3.82%
3 months: −3.42%
6 months: −10.51%
Year to date: +7.30%
1 year: +23.63%

Valuation & ownership

Market cap: 1.55B
Enterprise value: 1.30B
P/E (ttm): 5.01
Forward P/E: 9.71
PEG ratio: 3.17
Price / book: 1.26
Price / sales (ttm): 3.52
EV / EBITDA: 6.66
EPS (ttm): 4.28
EPS (forward): 2.21
Beta (5y monthly): 0.38
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 72.25M
Float: 67.65M
Short % of float: 12.87%
Short ratio (days): 6.79
Held by insiders: 1.01%
Held by institutions: 108.77%
Avg volume (3m): 784.03K
50-day average: 20.96
200-day average: 21.80
52-week change: +23.63%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 57.6
vs 50-day SMA: +2.32%
vs 200-day SMA: −1.59%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 2.10%
Realised vol (20d, ann.): 24.2%
From 52-week high: −14.71%
From 52-week low: +29.84%

ANR

Analyst Consensus

5 analysts

Consensus

—

Mean target

35.00

+63.17% implied

Low 18.00Median 35.00High 46.00

Recommendation trend

Now4 / 0 / 1
1m ago3 / 0 / 1

Buy / hold / sell counts

DES

About Innoviva, Inc.

Yahoo Finance profile

Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 159
Headquarters: Burlingame, CA, United States
Website: inva.com
Officers

SEAS

Seasonality · INVA

2007–2026 · monthly returns

Strongest month Dec +5.03%Weakest month Jan −3.37%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	0.1	14.8	1.5	-1.3	-6.8	6.0	-7.7	-1.0	2.1	1.1			+7.3%
2025	7.4	-3.9	1.2	3.1	4.7	2.7	-9.6	12.4	-10.7	-0.3	19.4	-8.0	+15.2%
2024	1.0	-5.7	-0.3	-0.9	4.5	3.9	14.9	2.9	-0.4	1.3	-2.9	-8.6	+8.2%
2023	-4.5	-4.6	-6.8	4.3	15.0	-5.6	6.4	-5.9	1.9	-4.5	11.6	15.8	+21.1%
2022	-7.1	19.8	0.7	-11.8	-11.1	-2.7	-2.8	-8.2	-11.8	16.8	-3.2	0.9	−23.2%
2021	-3.1	-4.8	4.5	-4.2	17.5	-0.3	5.7	7.6	9.5	4.4	-4.2	3.2	+39.2%
2020	-2.5	-2.5	-12.7	20.6	-1.5	0.1	-3.1	-13.6	-10.8	3.4	-3.2	18.5	−12.5%
2019	-2.0	-8.2	-10.6	0.0	-2.6	6.5	-18.4	-2.4	-9.1	10.2	16.0	5.0	−18.9%
2018	2.8	6.3	7.5	-13.0	2.0	-6.7	2.5	2.6	5.0	-8.4	30.8	-4.4	+23.0%
2017	-0.9	9.0	19.7	-14.8	3.6	4.7	7.2	2.3	0.6	-13.3	7.2	8.2	+32.6%
2016	-4.9	17.0	7.4	-2.0	-8.6	-6.6	22.2	-13.8	-0.9	-6.3	0.4	3.5	+1.5%
2015	-20.4	60.2	-13.0	3.4	4.0	6.9	-15.2	-9.2	-48.4	22.3	5.4	13.9	−25.5%
2014	3.3	0.5	-16.4	-13.0	6.4	29.0	-27.1	8.6	-27.5	-6.3	-5.6	-6.5	−50.7%
2013	0.0	-8.8	16.4	42.9	3.8	10.0	0.1	-7.0	14.0	-10.3	3.1	-5.6	+60.3%
2012	-19.7	5.4	4.3	11.0	-4.4	7.4	31.1	-8.4	-2.8	-13.1	-0.1	-1.1	+0.6%
2011	-16.1	8.3	6.3	14.6	-5.8	-15.0	-3.7	-11.1	6.0	10.4	5.0	-5.3	−11.8%
2010	-16.1	-0.7	22.3	25.9	-24.2	-1.1	17.8	-18.4	66.3	1.4	22.6	0.4	+91.8%
2009	6.4	5.8	22.0	-15.7	3.3	-1.1	3.1	2.8	-5.7	-4.6	-5.8	-0.7	+5.5%
2008	1.2	-16.6	-36.0	18.6	8.3	-12.3	34.6	-14.7	-8.6	-45.6	-1.5	85.5	−36.5%
2007	11.1	-6.0	-8.5	12.3	3.7	-6.8	-16.3	17.3	-16.9	-4.1	-3.7	-19.1	−36.9%

INSD

Insider Activity · INVA

Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
May 17, 2026	Linden JosephineDirector	Stock Award(Grant) at price 0.00 per share.	15.2K	—
May 14, 2026	Raifeld PavelChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	1.1K	—
May 14, 2026	Basso StephenChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	1.1K	—
May 3, 2026	Dipaolo Mark ADirector	Stock Award(Grant) at price 0.00 per share.	9.8K	—
May 3, 2026	Zhen Marianne YOfficer	Stock Award(Grant) at price 0.00 per share.	12.8K	—
May 3, 2026	Raifeld PavelChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	126.6K	—
May 3, 2026	Basso StephenChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	38K	—
May 3, 2026	Haimovitz JulesDirector	Stock Award(Grant) at price 0.00 per share.	9.8K	—
May 3, 2026	Schlesinger Sarah JDirector	Stock Award(Grant) at price 0.00 per share.	9.8K	—
May 3, 2026	Small Derek ADirector	Stock Award(Grant) at price 0.00 per share.	9.8K	—
Nov 13, 2025	Basso StephenChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	604	—
Nov 2, 2025	Raifeld PavelBeneficial Owner of more than 10% of a Class of Security	Stock Award(Grant) at price 0.00 - 18.11 per share.	112.3K	$2.00M
Nov 2, 2025	Basso StephenChief Financial Officer	Stock Award(Grant) at price 18.11 per share.	27.6K	$500.00K
May 18, 2025	Dipaolo Mark ADirector	Stock Award(Grant) at price 0.00 per share.	12.1K	—
May 18, 2025	Haimovitz JulesDirector	Stock Award(Grant) at price 0.00 per share.	12.1K	—
May 18, 2025	Schlesinger Sarah JDirector	Stock Award(Grant) at price 0.00 per share.	12.1K	—
May 18, 2025	Small Derek ADirector	Stock Award(Grant) at price 0.00 per share.	12.1K	—
May 14, 2025	Basso StephenChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	1.4K	—
Mar 13, 2025	Raifeld PavelBeneficial Owner of more than 10% of a Class of Security	Stock Award(Grant) at price 17.39 per share.	37.4K	$649.99K
Mar 5, 2025	Denner Alexander JBeneficial Owner of more than 10% of a Class of Security	Sale at price 17.52 - 17.63 per share.	1.62M	$28.40M

CONG

Congress Trades · INVA

House reports since 2025

Members

0 last bought

Buys

~$0

Sells

~$450.0K

Net

−$450.0K

est. bought − sold

Latest

Mar 25, 25

George Whitesides

Members who traded it

Member	Buys	Sells	Est. net	Last move
George Whitesides CA27		2	−$450.0K	Sold Mar 25, 25

Bought and sold by quarter (est.)

House members' INVA trades, newest first
Traded	Member	Owner	Type	Amount	Filed	Report
Mar 25, 25	George Whitesides CA27	Spouse	Sell	$250,001 - $500,000	Apr 23, 25 (29d)	PDF
Mar 24, 25	George Whitesides CA27	Self	Sell	$50,001 - $100,000	Apr 23, 25 (30d)	PDF

From the House's STOCK Act reports (Senate not included). Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades

INVA

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

INVA

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Innoviva, Inc.

Seasonality · INVA

Insider Activity · INVA

Congress Trades · INVA

Members who traded it

Bought and sold by quarter (est.)

Congress Trades · INVA

Members who traded it

Bought and sold by quarter (est.)

Insider Activity · INVA

Seasonality · INVA

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Innoviva, Inc.

Financial Snapshot

Earnings & Dividends

News